High gamma-aminobutyric acid level in cortical tubers in epileptic infants with tuberous sclerosis complex measured with the MEGA-editing J-difference method and a three-Tesla clinical MRI Instrument

NeuroImage

Volumn 47, Issue 4, 2009, Pages 1207-1214

  Taki, Masako Minato ^a   Harada, Masafumi ^a   Mori, Kenji ^a   Kubo, Hitoshi ^a   Nose, Ayumi ^a   Matsuda, Tsuyoshi ^b   Nishitani, Hiromu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b GE Yokogawa Medical Systems Ltd   (Japan)

Author keywords

GABA; Glutamate; MEGA; Proton MRS; Tuberous sclerosis

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID;

ARTICLE; BRAIN CORTEX; BRAIN DISEASE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICAL TUBER; DIAGNOSTIC PROCEDURE; EPILEPSY; FEMALE; GRAY MATTER; HUMAN; HYPOTHESIS; MALE; NERVOUS SYSTEM DEVELOPMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TUBEROUS SCLEROSIS; WHITE MATTER;

BIOLOGICAL MARKERS; CEREBRAL CORTEX; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TUBEROUS SCLEROSIS;

EID: 67651064325     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2009.05.060     Document Type: Article

References (33)

1. Aasly J., Silfvenius H., Aas T.C., Sonnewald U., Olivecrona M., Juul R., and White L.R. Proton magnetic resonance spectroscopy of brain biopsies from patients with intractable epilepsy. Epilepsy Res. 35 (1999) 211-217
2. Ben-Ari Y. Excitatory actions of GABA during development: the nature of the nurture. Nat. Rev. Neurosci. 3 (2002) 728-739
3. Ben-Ari Y., and Holmes G.L. The multiple facets of γ-aminobutyric acid dysfunction in epilepsy. Curr. Opin. Neurol. 18 (2005) 141-145
4. Ben-Ari Y., Gaiarsa J.-L., Tyzio R., and Khazipov R. GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiol. Rev. 87 (2006) 1215-1261
5. Choi C., Bhardwaj P.P., Kalra S., Casault C.A., Yasmin U.S., Allen P.S., and Coupland N.J. Measurement of GABA and contaminants in gray and white matter in human brain in vivo. Magn. Reson. Med. 58 (2007) 27-33
6. Choi C.G., and Frahm J. Localized proton MRS of the human hippocampus metabolites concentrations and relaxation times. Magn. Reson. Med. 41 (1999) 204-207
7. Choi I.-Y., Lee S.-P., Merkle H., and Shen J. In vivo detection of gray and white matter differences in GABA concentration in the human brain. NeuroImage 33 (2006) 85-93
8. Constantinidis I. MRS methodology. Adv. Neurol. 83 (2000) 235-246
9. Harada M., Miyoshi H., Uno M., Okada T., Hisaoka S., Hori A., and Nishitani H. Neuronal impairment of adult moyamoya disease detected by quantified proton MRS and comparison with cerebral perfusion by SPECT with Tc-99m HM-PAO: a trial of clinical quantification of metabolites. J. Magn. Reson. Imaging 10 (1999) 124-129
10. Hashimoto T., Tayama M., Miyazaki M., Fujii E., Harada M., Miyoshi H., Tanouchi M., and Kuroda Y. Developmental brain changes investigated with proton magnetic resonance spectroscopy. Dev. Med. Child Neurol. 37 (1995) 398-405
11. Jensen J.E., de Frederick B., and Renshaw P.F. Gray and white matter GABA level differences in the human brain using two-dimensional, J-resolved spectroscopic imaging. NMR Biomed. 18 (2005) 570-576
12. Khazipov R., Khalilov I., Tyzio R., Morozova E., Ben-Ari Y., and Hlmes G.L. Developmental changes in GABAergic actions and seizure susceptibility in the rat hippocampus. Eur. J. Neruosci. 19 (2004) 590-600
13. Kreis R., Ernst T., and Ross B.D. Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn. Reson. Med. 30 (1993) 424-437
14. 1H-MR spectroscopy and clinical manifestation with tuberous sclerosis complex. Neuropediat. 38 (2006) 126-129
15. Mescher M., Tannus A., Johnson M.O.'N., and Garwood M. Solvent suppression using selective echo dephasing. J. Magn. Reson. Series A 123 (1996) 226-229
16. Mescher M., Merkle H., Kirsh J., Garwood M., and Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 11 (1998) 266-272
17. Mizuno S., Takahasi Y., Kato Z., Goto H., Kondo N., and Hoshi H. Magnetic resonance spectroscopy of tubers in patients with tuberous sclerosis. Acta Neurol. Scand. 102 (2000) 175-178
18. Mukonoweshuro W., Wilkinson I.D., and Griffiths P.D. Proton MR spectroscopy of cortical tubers in adults with tuberous sclerosis complex. Am. J. Neuroradiol. 22 (2001) 1920-1925
19. Novotny E.J., Hyder F., Shevell M., and Rothman D.L. GABA changes with vigabatrin in the developing human brain. Epilepsia 40 (1999) 462-466
20. Öz G., Terpstra M., Tkac I., Aia P., Lowary J., Tuite P.J., and Gruetter R. Proton MRS of the unilateral substantia nigra in the human brain at 4 Tesla: detection of high GABA concentrations. Magn. Reson. Med. 55 (2006) 296-301
21. Petroff O.A.C., Ogino T., and Alger J.R. High resolution proton magnetic resonance spectroscopy of rabbit brain: regional metabolite levels and postmortem changes. J. Neurochem. 51 (1988) 163-171
22. Petroff O.A.C., Rothman D.L., Behar K.L., and Mattson R.H. Initial observations on effect of vigabatrin on in vivo 1H spectroscopic measurements of γ-aminobutyric acid, glutamate, and glutamine in human brain. Epilepsia 36 (1995) 457-464
23. Petroff O.A.C., Behar K.L., Mattson R.H., and Rothman D.L. Human brain γ-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy. J. Neurochem. 67 (1996) 2399-2404
24. Petroff O.A.C., Rothman D.L., Behar K.L., Hyder F., and Mattson R.H. Effect of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures. Seizure 8 (1999) 120-127
25. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 30 (1993) 672-679
26. Roach E.S., Williams D.P., and Laster W. Magnetic resonance imaging in tuberous sclerosis. Arch. Neurol. 44 (1987) 301-303
27. Sharma M.S., Suri A., Shah T., Ralte A., Sarkar C., Gupta V., and Mehta V.S. Intraventricular glioneuronal hamartoma: histopathological correlation with magnetic resonance spectroscopy. J. Neurooncol. 74 (2005) 325-328
28. Shepherd C.W., Houser W., and Gomez M.R. MR findings in tuberous sclerosis complex and correlation with seizure development and mental impairment. Am. J. Neuroradiol. 16 (1995) 149-155
29. Simister R.J., McLean M.A., Barker G.J., and Duncan J.S. A proton magnetic resonance spectroscopy study of metabolites in the occipital lobes in epilepsy. Eplepsia. 44 (2003) 550-558
30. Simister R.J., McLean M.A., Barker G.J., and Duncan J.S. Proton magnetic resonance spectroscopy of malformations of cortical development causing epilepsy. Epilepsy Res. 74 (2007) 107-115
31. Terpstra M., Henry P.-G., and Gruetter R. Measurement of reduced glutathione (GSH) in human brain using LCModel analysis of difference-edited spectra. Magn. Reson. Med. 50 (2003) 19-23
32. Weber O.M., Verhagen A., Duc C.O., Meier D., Leenders K.L., and Boesiger P. Effects of vigabatrin intake on brain GABA activity as monitored by spectrally edited magnetic resonance spectroscopy and positron emission tomography. Magn. Reson. Imaging 17 (1999) 417-425
33. Yapici Z., Dortcan N., Baykan B.B., Okan F., Dincer A., Baykal C., Eraksoy M., and Roach S. Neurological aspects of tuberous sclerosis in relation to MRI/MR spectroscopy findings in children with epilepsy. Neurol. Res. 29 (2007) 449-454